Ten-year evolution of mechanical ventilation in acute respiratory failure in the hematological patient admitted to the intensive care unit

A. Belenguer-Muncharaz*, L. Albert-Rodrigo, A. Ferrandiz-Sellés, G. Cebrián-Graullera

Servicio de Medicina Intensiva, Hospital General de Castellón, Castellón de la Plana, Spain

Received 27 August 2012; accepted 21 December 2012
Available online 13 November 2013

Abstract

Objective: A comparison was made between invasive mechanical ventilation (IMV) and non-invasive positive pressure ventilation (NPPV) in hematological patients with acute respiratory failure.

Design: A retrospective observational study was made from 2001 to December 2011.

Setting: A clinical–surgical intensive care unit (ICU) in a tertiary hospital.

Patients: Patients with hematological malignancies suffering acute respiratory failure (ARF) and requiring mechanical ventilation in the form of either IMV or NPPV.

Variables of interest: Analysis of infection and organ failure rates, duration of mechanical ventilation and ICU and hospital stays, as well as ICU, hospital, and mortality after 90 days. The same variables were analyzed in the comparison between NPPV success and failure.

Results: Forty-one patients were included, of which 35 required IMV and 6 NPPV. ICU mortality was higher in the IMV group (100% vs 37% in NPPV, p = .006). The intubation rate in NPPV was 40%. Compared with successful NPPV, failure in the NPPV group involved more complications, a longer duration of mechanical ventilation and ICU stay, and greater ICU and hospital mortality. Multivariate analysis of mortality in the NPPV group identified NPPV failure (OR 13 [95% CI 1.33–77.96], p = .008) and progression to acute respiratory distress syndrome (OR 10 [95% CI 1.95–89.22], p = .03) as prognostic factors.

Conclusion: The use of NPPV reduced mortality compared with IMV. NPPV failure was associated with more complications.

© 2012 Elsevier España, S.L., and SEMICYUC. All rights reserved.
Introduction

The prognosis of malignant hematological disease has improved over the last few decades,\(^1,2\) though patients requiring admission to the intensive care unit (ICU) continue to present a high mortality rate.\(^1,3^\--^5\) The main cause of admission to the ICU is the development of acute respiratory failure (ARF), sometimes requiring ventilatory support,\(^1,2\) due to the appearance of both infectious and non-infectious pulmonary infiltrates.\(^6\) On the other hand, mechanical ventilation (MV), and particularly invasive mechanical ventilation (IMV), has been shown to be one of the risk factors of mortality in the ICU.\(^1,2\)

The development of noninvasive positive pressure ventilation (NPPV) as a ventilatory support technique has represented a great step forward in the ventilatory care of critically ill patients. NPPV offers a series of benefits,\(^9,10\) since it lessens the need for orotracheal intubation thanks to resting of the muscle burden generated by the respiratory disease underlying ARF; improves oxygenation; and facilitates the elimination of carbon dioxide. As a direct consequence of this, NPPV is able to reduce the incidence of ventilator associated pneumonia (VAP) and shorten patient stay in the ICU and in hospital, especially in immune depressed individuals. Nevertheless, despite these reported benefits and the existence of studies supporting the success of the technique,\(^4,10^\--^13\) NPPV is still less widely used than expected, and IMV remains the gold standard for the ventilation support of these patients.\(^6\)

The present study analyzes the incidence of ARF in hematological patients admitted to the ICU and requiring mechanical ventilation (invasive and noninvasive), with the purpose of determining whether NPPV is superior to IMV in terms of the development of infections, organ failure, the duration of mechanical ventilation, the duration of stay in the ICU and in hospital, and mortality in the ICU, in hospital, and after 90 days. Likewise, an analysis was made of the incidence of NPPV failure, comparing the same variables between the success and failure groups, and of the factors related to mortality in the NPPV group.

Materials and methods

A retrospective observational was carried out, following approval by the hospital Clinical Research Ethics Committee. We included all hematological patients with ARF admitted to the ICU between January 2001 and December 2011, and who required ventilatory support. The hematological diseases mainly comprised acute leukemia (lymphoblastic or myelocytic), non-Hodgkin lymphoma, multiple myeloma, chronic leukemia and Hodgkin’s disease. The patients had received chemotherapy, corticosteroid therapy or treatment in the form of hematopoietic precursor cell transplantation. Neutropenia was defined as a leukocyte count of under 1000 cells/mm\(^3\).

Acute respiratory failure was defined as a respiratory frequency (RF) of >30 rpm, a partial oxygen pressure (PaO\(_2\)) of <60 mmHg or a partial carbon dioxide pressure (PaCO\(_2\)) of >45 mmHg. Community-acquired pneumonia (CAP) was considered as a lower airway infection characterized by opacifications on the chest X-rays, signs and symptoms of respiratory infection such as fever, cough, pleuritic pain, leukocytosis or leukopenia, and the presence or absence of secretions.\(^14\) Hypoxemic conditions were classified as acute lung injury (ALI) or adult respiratory distress
syndrome (ARDS), based on the following criteria: bilateral infiltration, pulmonary wedge pressure < 18 mmHg, PaO₂/FiO₂ < 300 (ALI) or PaO₂/FiO₂ < 200 (ARDS). For the microbiological study we determined soluble antigens in urine, and peripheral blood samples were obtained for blood culture and pneumonia serological testing. Lastly, where possible, we obtained sputum for culture and gram staining. Nasopharyngeal aspiration in turn was performed for determination of the new H1N1 influenza virus – this test being carried out on a routine basis since 2009 in all cases of pneumonia exhibiting an interstitial radiological pattern. Non-bronchoscopic invasive samples (bronchoalveolar lavage and bronchial aspirate), were collected once the patients were intubated. The criteria for sepsis and septic shock were established according to the literature.

Monitorization and study variables

Upon patient admission, invasive hemodynamic monitorization was carried out, with arterial catheterization and a central venous line. Respiratory monitorization in turn was carried out by recording transcutaneous oxygen saturation (SatcO₂) with an Oxidensor Nellcor II D-25 pulsoxymeter (Nellcor® Puritan Bennet Inc., Decasanton, CA, USA), and arterial blood samples were obtained for blood gas determinations using an ABL560 cooxymeter (Radiometer Medical A/S®, Copenhagen, Denmark).

Upon patient admission and during the stay in the ICU, we collected personal data and information referred to the diagnosis, severity based on the Simplified Acute Physiology Score (SAPS) 2 and organ failure based on the Sequential Organ Failure Assessment (SOFA). We also recorded the corresponding hemodynamic, respiratory, blood gas and biochemical variables. The duration of stay in the ICU and in hospital was registered, along with the duration of mechanical ventilation. In turn, the complications occurring during stay in the Unit were documented, such as orotracheal intubation, barotrauma, nosocomial infections, the need for tracheotomy and mortality (in the ICU, in hospital, and 90 days after admission). The organ dysfunction rate was assessed based on the Marshall scale, which contemplates acute renal failure (with or without hemofiltration) and cardiovascular, hematological, neurological and hepatic failure.

Noninvasive ventilatory support

Use was made of the BiPAP Vision® (Respironics Inc.®, PA, USA) connected to an orofacial or Total face® mask (Respironics Inc.®, PA, USA) with an MR850 active humidification system (Fischer and Paykel Healthcare Ltd., New Zealand). After explaining the technique to the patient, the mask was fitted and we progressively increased the positive end-expiratory pressure (PEEP) and the support pressure to above the PEEP (SP), until achieving a tidal volume (VT) of 10–15 ml/kg and a RR of 25–28 rpm, thereby ensuring a minimum SP of 10–15 cmH₂O and a PEEP of 5–6 cmH₂O in the first hour of ventilatory support. The oxygen concentration was adjusted until reaching SatcO₂ > 94%. Once the clinical and/or blood gas condition of the patient improved, gradual ventilator withdrawal was carried out until complete disconnection of NPPV. The changes in FiO₂ and SP/PEEP levels were made according to the criterion of the supervising physician. NPPV failure was considered in the presence of any of the following criteria: persistence of respiratory effort or hypoxemia, cognitive impairment, or asynchrony with the respirator.

Invasive ventilatory support

Patient sedation was carried out with midazolam or propofol associated to morphine, followed by orotracheal intubation and connection to the respirator. Initial parameters: volume control/assist ventilation (CMV/a), VT: 6–8 ml/kg, flow 60l/min, RF: 12–14 rpm, FiO₂ to achieve SatcO₂ 94–96%, and minimum PEEP 5 cmH₂O. Progression of the respiratory process to ARDS required modification of the ventilatory parameters: VT < 6 ml/kg, plateau pressure < 35 cmH₂O, progressive PEEP and FiO₂ as low as possible with the aim of achieving SatcO₂ > 94%. After recovery, weaning was started, followed by extubation with the spontaneous breathing test. The modifications of the ventilatory parameters and weaning were carried out by the supervising physician. The patient was considered to have passed the breathing test if there was no hemodynamic or respiratory worsening during 2 h. In such cases extubation was considered indicated, always conditioned to medical criterion.

The duration of mechanical ventilation included the time (in days) of mechanical ventilation and the weaning time. Hospital stay in turn was documented as the total stay of the patient in the ICU and in hospital. The application of IMV or NPPV, along with the rest of supportive measures (vasoactive drugs, antibiotherapy, renal replacement therapy, blood product transfusion, nutritional support), was regarded as the responsibility of the attending physician at the time of admission, in collaboration with the Department of Hematology.

Given the characteristics of the study, informed consent from the patient and/or family was not considered necessary.

Statistical analysis

The SPSS version 18.0 statistical package was used for analysis of the results. Quantitative variables were analyzed using parametric (Student t-test) or nonparametric tests (Mann–Whitney U-test), according to the results of the Kolmogorov–Smirnov test for the assessment of normal distributions. Qualitative variables in turn were analyzed using the chi-squared test, with the Fisher exact test (2-tailed) when the number of cases was under 5. Statistical significance was considered for p < 0.05. Multivariate analysis was performed based on a logistic regression model to identify factors related to mortality in the NPPV group. We decided not to include the IMV group in the analysis, in order to avoid bias resulting from the inclusion of a group of patients who upon admission showed significant differences with respect to the NPPV group. The variables were included in the model using the enter method with a cutoff point of 0.1. The predictive capacity of the model was established from the Hosmer–Lemeshow test, the
positive predictive value, the negative predictive value, diagnostic accuracy, and analysis of the area under the receiver operating characteristic (ROC) curve.

Results

During the study period, a total of 132 patients with hematological disease were admitted to the ICU, out of a total of 11,501 hospitalized patients. Of the mentioned 132 patients, 41 required ventilatory support (31%): NPPV in 35 cases (85%) and IMV in 6 (15%). The patient sample (Table 1) consisted mainly of males (n = 26; 63%), with a mean age of 56 ± 6 years, a SOFA score of 7 ± 3, and a SAPS 2 score of 63 ± 18. Comparison of the two groups showed that upon admission, the IMV group had a greater incidence of organ failure as assessed by the SOFA (9 ± 4 vs 7 ± 2 in NPPV, p = 0.025), and a poorer prognosis as determined by the SAPS 2 (66 ± 17 vs 52 ± 14 in NPPV, p = 0.047). In contrast, the time to admission to the ICU was shorter in the NPPV group (3 [1–15] vs 26 [4–43] in IMV, p = 0.033). Most of the patients came from hospital wards, where in some cases continuous positive airway pressure (CPAP) had been applied as a step prior to admission to the ICU. The most frequent comorbid condition in both groups was arterial hypertension, the predominant disease was acute leukemia, and the cause of ARF was pneumonia, without significant differences. The percentage of neutropenia was greater in the IMV group (83% vs 26% in NPPV, p = 0.018). Comparison of the physiological parameters at baseline showed the IMV group to have more metabolic acidosis secondary to base excess (−9 ± 7 vs −2 ± 6 in NPPV, p = 0.013), thrombopenia (14,500 [11,000–21,000] vs 96,000 [29,000–239,000] in NPPV, p = 0.001), leukopenia (35 [20–100] vs 7210 [670–14,445] in NPPV, p = 0.003), coagulopathy as determined by the Quick index (51 [21–65] vs 70 [52–81] in NPPV, p = 0.05) and liver failure as estimated by bilirubin concentration (5 [3.12–5.00] vs 1 [0.79–1.55] in NPPV, p = 0.022).

Regarding the clinical course (Table 2), there were no significant differences between IMV and NPPV regarding the percentage of infections, organ failure rate, duration of mechanical ventilation, or stay in the ICU and in hospital. The mortality rate both in the ICU and in hospital (Table 2 and Fig. 1) was significantly higher in the IMV group (100% vs 37% in NPPV, p = 0.006, in the ICU; and 100% vs 46% in NPPV, p = 0.023, in hospital).

Within the NPPV group, on comparing success versus failure of the technique, no significant differences were observed in relation to the demographic characteristics, comorbidities or cause of respiratory failure (Table 1). Comparison of the physiological parameters showed differences between the success and failure of NPPV in terms of the level of PaO2 (82 [59–126] vs 58 [41–76], p < 0.005), bicarbonate (24 ± 6 vs 19 ± 5, p < 0.005), excess base deficit (0 ± 6 vs −5 ± 4, p < 0.005), and blood hemoglobin (9 ± 1 vs 10 ± 2, p < 0.005). The intubation rate was 40% (Table 2), which implies a greater organ dysfunction rate in this group, particularly as regards cardiovascular failure with the need for vasoactive support (100% vs 38% in the patients with successful NPPV, p = 0.0001). There were no significant differences in infection rate, though a shorter duration of mechanical ventilation, a shorter stay in the ICU, and a lesser mortality rate both in the ICU and in hospital were recorded in the group of patients with successful NPPV. The mortality rate after 90 days was significantly lower (p = 0.001) in the case of successful NPPV versus either failed NPPV or the IMV group (Fig. 1).

The multivariate analysis of all the variables significantly related to mortality in the NPPV group (Table 3) found the failure of NPPV (OR 13 [95% CI 1.95–89.22], p = 0.008) and the development of ARDS (OR 10 [95% CI 1.33–77.9], p = 0.03) to be related to mortality in the NPPV group. The positive predictive value of the model was 100%, with a negative predictive value of 59%, and a diagnostic accuracy of 74%. The area under the ROC curve was 0.88 (95% CI 0.773–0.993). The Hosmer–Lemeshow test with 4 degrees of freedom (d.f.) was not significant (p = 0.525).

Discussion

Our retrospective study found hematological patients admitted to the ICU and subjected to mechanical ventilation due to ARF to have lesser mortality than in other series, and the use of NPPV constituted a key element in the supportive measures, since it influenced the decrease in mortality among such patients.

Of note in our series is the use of NPPV as ventilatory support measure; in this sense, it is common practice in our Unit to make an attempt with this technique before considering IMV. Such practice has also been extended to the hospitalization ward, where a percentage of admitted patients receive ventilatory support with CPAP as a step prior to admission to the ICU. A randomized study showed that the use of CPAP versus oxygen therapy in the Hematology ward in patients with ARF reduced progression toward ARDS, the need for admission to the ICU, and the need for invasive ventilatory support. Despite these results, the application of CPAP in our small sample was greater in the group in which NPPV failed, and did not result in benefit of any kind. In our series, intubation from the start was limited to patients with multiorgan dysfunction as assessed by the SOFA score, which was higher than in the NPPV group—though not all the values reached statistical significance. This increased severity could account for the poor results obtained in the IMV group, since all the patients died in the ICU during the first hours, and mostly under conditions of multiorgan failure—this proportion being greater than expected from the SAPS 2 score. Different authors have underscored the predictive value of multiorgan failure in relation to mortality, though it should be taken into account that most patients upon admission, at least in our series, already presented dysfunction of several organs. In this sense, our data coincide with the findings of a Spanish multicenter study that analyzed the ventilatory support measures in hematological patients, and in which the SOFA score was higher in those patients directly subjected to IMV versus the NPPV group, and the initial respiratory SOFA score was similar in the IMV and NPPV (success and failure) groups—though in the NPPV failure group the score worsened significantly with respect to the rest of the patients over time.

In our opinion, NPPV has been a determinant factor in the reduction of mortality, since as we have seen, the number of complications and infections was not significantly
Table 1  Demographic characteristics, comorbidities and cause of acute respiratory failure.

<table>
<thead>
<tr>
<th>Variables</th>
<th>Global (n = 41)</th>
<th>NPPV (n = 35)</th>
<th>NPPV success (n = 21)</th>
<th>NPPV failure (n = 14)</th>
<th>IMV (n = 6)</th>
<th>p*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex, male (n = 26), n (%)</td>
<td>26 (63)</td>
<td>22 (63)</td>
<td>13</td>
<td>9</td>
<td>4 (67)</td>
<td>1.000</td>
</tr>
<tr>
<td>Age**, years</td>
<td>56 ± 6</td>
<td>58 ± 14</td>
<td>59 ± 12</td>
<td>57 ± 20</td>
<td>50 ± 12</td>
<td>0.280</td>
</tr>
<tr>
<td>SOFAa</td>
<td>7 ± 3</td>
<td>7 ± 2</td>
<td>7 ± 2</td>
<td>7 ± 3</td>
<td>9 ± 4</td>
<td>0.025</td>
</tr>
<tr>
<td>SAPS 2 (%)</td>
<td>63 ± 18</td>
<td>52 ± 14</td>
<td>53 ± 17</td>
<td>50 ± 11</td>
<td>66 ± 17</td>
<td>0.047</td>
</tr>
<tr>
<td>SAPS 2 (%)</td>
<td>54 ± 26</td>
<td>49 ± 25</td>
<td>51 ± 28</td>
<td>48 ± 20</td>
<td>73 ± 29</td>
<td>0.054</td>
</tr>
<tr>
<td>Time to admission to UCFc</td>
<td>3 (1–15)</td>
<td>3 (1–15)</td>
<td>3 (1–15)</td>
<td>4 (1–16)</td>
<td>26 (4–43)</td>
<td>0.033</td>
</tr>
<tr>
<td>CPAP prior to admission, n (%)</td>
<td>10 (24)</td>
<td>8 (23)</td>
<td>3 (14)</td>
<td>5 (35)</td>
<td>2 (33)</td>
<td>0.622</td>
</tr>
<tr>
<td>Origin of patients, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical or surgical ward</td>
<td>33 (80)</td>
<td>28 (80)</td>
<td>17 (80)</td>
<td>11 (78)</td>
<td>5 (83)</td>
<td></td>
</tr>
<tr>
<td>Emergencies</td>
<td>6 (15)</td>
<td>6 (17)</td>
<td>3 (14)</td>
<td>3 (12)</td>
<td>0</td>
<td>0.567</td>
</tr>
<tr>
<td>Operating room</td>
<td>1 (2)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1 (17)</td>
<td>0.000</td>
</tr>
<tr>
<td>Other ICU</td>
<td>1 (2)</td>
<td>1 (3)</td>
<td>1 (6)</td>
<td>0</td>
<td>0</td>
<td>1.000</td>
</tr>
<tr>
<td>Comorbidities, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arterial hypertension</td>
<td>17 (41)</td>
<td>16 (46)</td>
<td>12 (57)</td>
<td>4 (28)</td>
<td>1 (17)</td>
<td>0.382</td>
</tr>
<tr>
<td>COPD</td>
<td>6 (15)</td>
<td>6 (17)</td>
<td>5 (24)</td>
<td>1 (7)</td>
<td>0</td>
<td>0.567</td>
</tr>
<tr>
<td>Congestive heart failure</td>
<td>4 (10)</td>
<td>4 (11)</td>
<td>3 (14)</td>
<td>1 (7)</td>
<td>0</td>
<td>1.000</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>4 (10)</td>
<td>4 (11)</td>
<td>4 (19)</td>
<td>0</td>
<td>0</td>
<td>1.000</td>
</tr>
<tr>
<td>Previous cancerd</td>
<td>4 (10)</td>
<td>3 (8)</td>
<td>2 (9)</td>
<td>1 (7)</td>
<td>1 (17)</td>
<td>0.483</td>
</tr>
<tr>
<td>Smoking</td>
<td>3 (7)</td>
<td>3 (8)</td>
<td>2 (9)</td>
<td>1 (7)</td>
<td>0</td>
<td>0.683</td>
</tr>
<tr>
<td>Chronic renal failure</td>
<td>1 (2)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1 (17)</td>
<td>0.146</td>
</tr>
<tr>
<td>Neutropenia, n (%)</td>
<td>14 (34)</td>
<td>9 (26)</td>
<td>5 (24)</td>
<td>4 (28)</td>
<td>5 (83)</td>
<td>0.013</td>
</tr>
<tr>
<td>Type of hematological disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.608</td>
</tr>
<tr>
<td>Acute leukemia, n (%)</td>
<td>18 (44)</td>
<td>13 (37)</td>
<td>7 (33)</td>
<td>6 (43)</td>
<td>5 (83)</td>
<td></td>
</tr>
<tr>
<td>Non-Hodgkin lymphoma, n (%)</td>
<td>9 (22)</td>
<td>9 (26)</td>
<td>7 (33)</td>
<td>2 (14)</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Multiple myeloma, n (%)</td>
<td>8 (19)</td>
<td>7 (20)</td>
<td>5 (24)</td>
<td>2 (14)</td>
<td>1 (17)</td>
<td></td>
</tr>
<tr>
<td>Othersd, n (%)</td>
<td>6 (15)</td>
<td>6 (17)</td>
<td>2 (10)</td>
<td>4 (29)</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Cause of acute respiratory failure, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumonia†</td>
<td>16 (39)</td>
<td>15 (43)</td>
<td>8 (38)</td>
<td>7 (50)</td>
<td>1 (17)</td>
<td></td>
</tr>
<tr>
<td>Sepsisd</td>
<td>16 (39)</td>
<td>12 (33)</td>
<td>7 (33)</td>
<td>5 (35)</td>
<td>4 (66)</td>
<td></td>
</tr>
<tr>
<td>ARF of pulmonary origin†</td>
<td>6 (14)</td>
<td>6 (17)</td>
<td>5 (24)</td>
<td>1 (7.5)</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Acute lung edema</td>
<td>1 (2)</td>
<td>1 (3.3)</td>
<td>1 (5)</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Postoperative ARF</td>
<td>1 (2)</td>
<td>1 (3.3)</td>
<td>0</td>
<td>1 (7.5)</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>TRALI</td>
<td>1 (2)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1 (17)</td>
<td></td>
</tr>
</tbody>
</table>

CPAP, continuous positive airway pressure; COPD, chronic obstructive pulmonary disease; ARF, acute respiratory failure; SAPS 2, Simplified Acute Physiology Score (range 0–56); SOFA, Sequential Organ Failure Assessment; TRALI, transfusion-related acute lung injury; ICU, Intensive Care Unit; IMV, invasive mechanical ventilation; NPPV, noninvasive positive pressure ventilation.

a Mean ± SD; the rest as percentage.
b Median and 25–75% interquartile range; the rest as percentage.
c Causes of intubation: urgent surgery (2 cases), urgent intubation in ward due to respiratory fatigue (2 cases), severe hypoxemia (1 case) and diminished consciousness (1 case).
d Causes of cancer: NPPV (prostate, ear, nose and throat, gastrointestinal), IMV (gynecological).
e Bone marrow aplasia (1 case), hyaline-vascular type Castleman’s disease (1 case), chronic leukemia (2 cases), Hodgkin’s disease (2 cases).
f Cause of pneumonia: pneumococcus (3 cases), H1N1 influenza (1 case), rest unknown.
g Causes of sepsis: bacteremia (5 cases in NPPV and 1 case in IMV), unknown focus (4 cases in NPPV), urological (1 case in NPPV), infections from blood products (1 case in NPPV), soft tissues (2 cases in IMV), ear, nose and throat (1 case in IMV), abdominal (1 case in NPPV).
h Causes of pulmonary ARF: adult respiratory distress syndrome (4 cases), pleural effusion (1 case), possible pulmonary hemorrhage (1 case).

* Comparison NPPV vs IMV.
Table 2  Comparison of complication rates, duration of ventilation and duration of stay between NPPV (both success and failure) and IMV.

<table>
<thead>
<tr>
<th></th>
<th>NPPV (n = 35)</th>
<th>IMV (n = 6)</th>
<th>( p^{**} )</th>
<th>( p^{*} )</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Global NPPV (n = 35)</td>
<td>Success NPPV (n = 21)</td>
<td>Failure NPPV (n = 14)</td>
<td></td>
</tr>
<tr>
<td>VAP, n (%)</td>
<td>2 (5)</td>
<td>0</td>
<td>2 (14)</td>
<td>0.153</td>
</tr>
<tr>
<td>Urinary infection, n (%)</td>
<td>3 (8)</td>
<td>1 (5)</td>
<td>2 (14)</td>
<td>0.551</td>
</tr>
<tr>
<td>Bacteremia, n (%)</td>
<td>13 (36)</td>
<td>7 (33)</td>
<td>6 (43)</td>
<td>0.724</td>
</tr>
<tr>
<td></td>
<td><strong>Primary bacteremia</strong></td>
<td>3</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td><strong>Catheter-related bacteremia</strong></td>
<td>5</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td><strong>Secondary bacteremia</strong></td>
<td>5</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Organ failure, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>22 (63)</td>
<td>8 (38)</td>
<td>14 (100)</td>
<td>0.0001</td>
</tr>
<tr>
<td>Hematological</td>
<td>21 (60)</td>
<td>12 (57)</td>
<td>9 (64)</td>
<td>0.737</td>
</tr>
<tr>
<td>ARDS</td>
<td>18 (51)</td>
<td>8 (38)</td>
<td>10 (71)</td>
<td>0.086</td>
</tr>
<tr>
<td>Renal</td>
<td>13 (37)</td>
<td>5 (24)</td>
<td>8 (57)</td>
<td>0.075</td>
</tr>
<tr>
<td>Hepatic</td>
<td>8 (23)</td>
<td>3 (14)</td>
<td>5 (36)</td>
<td>0.221</td>
</tr>
<tr>
<td>Neurological</td>
<td>4 (11)</td>
<td>2 (9)</td>
<td>2 (14)</td>
<td>1.000</td>
</tr>
<tr>
<td>Cardiac arrest, n (%)</td>
<td>3 (8)</td>
<td>0</td>
<td>3 (21)</td>
<td>0.056</td>
</tr>
<tr>
<td>Barotrauma, n (%)</td>
<td>2 (6)</td>
<td>0</td>
<td>2 (14)</td>
<td>0.153</td>
</tr>
<tr>
<td>Tracheostomy, n (%)</td>
<td>2 (6)</td>
<td>0</td>
<td>2 (14)</td>
<td>0.153</td>
</tr>
<tr>
<td>Duration mechanical ventilation(^b), days</td>
<td>8 ± 9</td>
<td>4 ± 3</td>
<td>13 ± 12</td>
<td>0.016</td>
</tr>
<tr>
<td>Stay in ICU(^b), days</td>
<td>11 ± 11</td>
<td>7 ± 4</td>
<td>18 ± 15</td>
<td>0.025</td>
</tr>
<tr>
<td>Stay in hospital(^b), days</td>
<td>34 ± 19</td>
<td>33 ± 19</td>
<td>32 ± 21</td>
<td>0.800</td>
</tr>
<tr>
<td>Mortality in ICU, n (%)</td>
<td>13 (37)</td>
<td>3 (14)</td>
<td>10 (71)</td>
<td>0.001</td>
</tr>
<tr>
<td>Causes of death</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Multorgan failure</td>
<td>9</td>
<td>2</td>
<td>7</td>
<td>5</td>
</tr>
<tr>
<td>Cardiac arrest</td>
<td>2</td>
<td>0</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Cerebral hemorrhage</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Refractory hypoxemia</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Mortality in hospital, n (%)</td>
<td>16 (46)</td>
<td>6 (28)</td>
<td>10 (71)</td>
<td>0.018</td>
</tr>
</tbody>
</table>

ARDS, adult respiratory distress syndrome; ICU, Intensive Care Unit; IMV, invasive mechanical ventilation; NPPV, noninvasive positive pressure ventilation; VAP, ventilator associated pneumonia.

\(^a\) Comparison of NPPV vs IMV.
\(^**\) Comparison of success vs failure of NPPV.
\(^b\) Secondary bacteremia foci: pulmonary (2 cases), urinary (3 cases), abdominal (1 case) and blood product bag infection by *Klebsiella oxytoca* (1 case).

Table 3  Multivariate analysis of factors related to mortality in the NPPV group.

<table>
<thead>
<tr>
<th></th>
<th>NPPV survivors (n = 22)</th>
<th>NPPV non-survivors (n = 13)</th>
<th>( p )</th>
<th>Odds ratio</th>
<th>95% CI</th>
<th>( p )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basal metabolic acidosis, n (%)</td>
<td>8 (36)</td>
<td>6 (46)</td>
<td>0.236</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Failure NPPV, n (%)</td>
<td>4 (18)</td>
<td>10 (77)</td>
<td>0.001</td>
<td>13.2</td>
<td>1.33–77.96</td>
<td>0.008</td>
</tr>
<tr>
<td>Hemodynamic failure, n (%)</td>
<td>11 (50)</td>
<td>11 (84)</td>
<td>0.07</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver failure, n (%)</td>
<td>2 (9)</td>
<td>6 (46)</td>
<td>0.032</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ARDS, n (%)</td>
<td>7 (32)</td>
<td>11 (85)</td>
<td>0.005</td>
<td>10.2</td>
<td>1.95–89.22</td>
<td>0.025</td>
</tr>
<tr>
<td>CRA, n (%)</td>
<td>0</td>
<td>3 (23)</td>
<td>0.04</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

95% CI, 95% confidence interval; CRA, cardiorespiratory arrest; ARDS, adult respiratory distress syndrome; NPPV, noninvasive positive pressure ventilation.
greater in the IMV group (mainly due to the brief stay in the ICU caused by early mortality)—though all of them considered jointly, together with the organ dysfunction already present at the time of admission, probably influenced the final results obtained. These results therefore reaffirm our opinion that whenever possible, NPPV should be used for initial ventilatory support, in concordance with the observations of most studies published to date, in which utilization of the technique has been associated with a high level of evidence. Nevertheless, recent studies continue to describe a greater use of IMV versus NPPV, though these same publications have shown NPPV to afford a substantial decrease in mortality compared with IMV. Another reason why our results are consistent with those obtained by other authors could be the close collaboration between the Department of Hematology and our Department of Intensive Care Medicine, thereby allowing earlier management of the many complications which these patients tend to present, and which are difficult to deal with in a hospitalization ward. The main element conditioning such close collaboration between our Departments was the introduction of NPPV in our range of therapeutic options. The high mortality associated with the need for IMV raised some doubts about admitting such patients to our Unit, in view of the important care burden involved (respiratory support, vasoactive and renal therapy in many cases, and the adoption of isolation measures), and the ominous outcomes. But the introduction of NPPV and the publication of studies warranting the use of this technique in immune depressed patients led to a substantial change in admission policy. Another consideration was the rapid development and severity of organ dysfunction in these patients, making it futile to admit such cases of established multiorgan failure to the ICU. Early intervention with early admission thus proved essential. In this same line, some studies point to the benefits in terms of lessened mortality of admitting patients with hematological malignancies to the ICU based on a less restrictive admission policy. In this sense, consideration is also required of the fact that a delay in admission to the ICU is directly correlated to mortality—thus advocating early patient admission.

In this scenario favorable to NPPV, doubts remain as to why the technique is still underused. The reason could be the high incidence of ARDS upon admission or during patient stay in the ICU, and the controversial indication of NPPV in ARDS. Different studies have shown NPPV in hypoxemic patients to be more effective than oxygen therapy, with particular emphasis upon ALI or ARDS—registering an NPPV failure rate of between 4.8% and 70% in ALI, and between 46% and 51% in patients with ARDS. The multivariate analysis found the development of ARDS to be a predictor of NPPV failure—this possibly being the reason why there is no clear recommendation on the use of NPPV in the context of ARDS, and why the technique is little used in hematological patients with severe hypoxemia. In contrast, however, the relationship between IMV and mortality in this

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>1d</th>
<th>2d</th>
<th>3d</th>
<th>4d</th>
<th>15d</th>
<th>30d</th>
<th>50d</th>
<th>90d</th>
</tr>
</thead>
<tbody>
<tr>
<td>NPPV-NO IOT</td>
<td>21</td>
<td>21</td>
<td>21</td>
<td>21</td>
<td>21</td>
<td>19</td>
<td>17</td>
<td>15</td>
<td>15</td>
</tr>
<tr>
<td>NPPV-IOT</td>
<td>14</td>
<td>11</td>
<td>10</td>
<td>10</td>
<td>9</td>
<td>8</td>
<td>6</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>IMV</td>
<td>6</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

Figure 1  Kaplan–Meier survival analysis (log-rank test) between the NPPV group (success and failure) and the IMV group after 90 days. Table: number of patients alive during this period of time. IMV, Invasive mechanical ventilation; NPPV, noninvasive positive pressure ventilation; NPPV OTI, intubated noninvasive ventilation; NPPV-NO OTI, non-intubated noninvasive ventilation.
Application of mechanical ventilation in patients with hematological
diseases has been well established.\(^{1,5,20-22}\) In this
sense, a multicenter observational study\(^{21}\) involving a series
of 1302 hematological patients with ARF showed the use of
NPPV to be less widespread than that of IMV (21% vs 79%).
The noninvasive group presented more neutropenia (16.8% vs
10%, \(p < 0.002\)) and hypoxemia than the invasive ventila-
tion group. In contrast, the patients in the IMV group were in
more serious condition as established by the APACHE score,
and had a poorer level of consciousness. This may have jus-
tified the initial use of IMV. A significant difference was also
noted in the use of NPPV versus IMV in patients with ALI
(21% vs 11%, \(p = 0.0001\)). In the case of patients with ARDS,
the difference failed to reach statistical significance. The
results showed the NPPV group to have a shorter duration of
mechanical ventilation and stay in the ICU, as well as lesser
mortality both in the ICU and in hospital, but these results
were not reproduced in the subgroup of patients with ALI or
ARDS. Another observational study\(^{6}\) found mortality after 30
days in the NPPV group to be significantly lower than in the
IMV group (43.7% vs 70.8%, \(p = 0.008\)).

On analyzing the NPPV group, failure of the technique
was seen to be associated with a greater complications
rate. These results coincide with those obtained in other
studies,\(^{10,22,24,30}\) where the failure of NPPV markedly
increased the percentage of complications, the duration
of stay, and mortality. In coincidence with other authors,\(^{20,22,27,28}\) we found mortality to be associated with failure of
NPPV and development of ARDS, along with other variables\(^{10,22}\)
such as age, septic shock, coma, coagulation disorders or a high SAPS 2 score, which were not analyzed in our series. Given the strong negative influence of NPPV failure upon mortality, it seems logical to explore the fac-
tors that influence such failure. In this context, different
studies\(^{24,28}\) have identified delayed introduction of ventila-
tory support, the development of ARDS, and the need for
vasoactive and renal support as predictors of NPPV failure.
Another cohort study of patients with ARDS\(^{30}\) found severity as
determined by a SAPS 2 score of >34, and the absence of
improvement in oxygenation (\(\text{PaO}_2/\text{FiO}_2 < 175\)) 60 min after
starting NPPV, to be predictors of failure. From the above it
can be concluded that NPPV will probably fail if the start of
the technique is delayed in a hypoxemic patient with scant
clinical and blood gas response after 1 h–intubation being
required in such cases.

The limitations of our study are represented by its
retrospective nature, and the fact that it was carried out
in a single center where NPPV moreover is routine practice
in patients with hypoxemic ARF.

Despite the poor results obtained in the IMV group, we
do not intend to discard the use of the technique. Rather,
we wish to underscore the benefits of NPPV in extremely ill
patients, with a poor prognosis and with multiple organ
dysfunction. The routine use of NPPV, and the risk of intubation
particularly in these patients, implies that the few individu-
als directly included in the IMV group were in a condition
in which NPPV was literally contraindicated. The conduction
of a prospective study comparing NPPV versus IMV with a lit-
erature basis\(^{5,7}\) demonstrating the mortality associated to
IMV, along with studies\(^{6,22}\) showing the good results obtained
with NPPV, therefore would be very questionable. Conse-
quentially, on the basis of our results, we could recommend
the use of NPPV as a first ventilatory support measure in
hematological patients with ARF, without considering the
classical NPPV indication criteria,\(^{10,16,21}\) and without
regarding ARDS or multiorgan dysfunction as exclusion
criteria–since at the time of admission to the ICU, most of
these patients already suffer dysfunction of one or more
organ systems.

Conflicts of interest

The authors declare that they have no conflicts of interest.

References

1. Kress JP, Christenson J, Pohlman AS, Linkin DR, Hall J. Out-
comes of critically ill cancer patients in a university hospital set-
2. Pène F, Aubron C, Azoulay E, Blot F, Thiéry G, Raynard B,
et al. Outcome of critically ill allogeneic hematopoietic stem-
cell transplantation recipients: a reappraisal of indications for
3. Kroschinsky F, Weise M, Illmer T, Haenel M, Bornhaeuser M, Hoef-
fen G, et al. Outcome and prognostic features of intensive care
unit treatment in patients with haematological malignancies.
4. Hampshire PA, Welch CA, McCrossan LA, Francis K, Harrison DA.
Admission factors associated with hospital mortality in patients
with haematological malignancy admitted to UK adult, general
critical care units: a secondary analysis of the ICNARC Case Mix
Outcomes and prognostic factors in patients with haematological
malignancy admitted to a specialist cancer intensive care unit:
6. Azoulay E, Alberti C, Bornstain C, Leleu G, Moreau D, Recher C,
et al. Improved survival in cancer patients requiring mechanical
ventilatory support: impact of non-invasive mechanical venti-
1
8. Shorr AF, Susla GM, O’Grady NP. Pulmonary infiltrates in the
non-HIV-infected immunocompromised patient: etiologies, diagno-
1
10. Evans TW. International Consensus Conference in Intensive Care
Medicine: non-invasive positive pressure ventilation in acute
respiratory failure. Organised jointly by the American Thoracic
Society, the European Respiratory Society, the European Society
of Intensive Care Medicine, and the Société de Réanimation de
Langue Française, and approved by the ATS Board of Directors,
Noninvasive ventilation for the treatment of acute respiratory
Noninvasive ventilation for treatment of acute respiratory fail-
ure undergoing solid organ transplantation: a randomized trial.
Dupon M, et al. Noninvasive ventilation in immunosuppressed
patients with pulmonary infiltrates, fever, and acute respiratory
14. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell
GD, Dean NC, et al. Infectious Diseases society of


